Nevertheless, the profiles of all tested biomarkers across the whole panel of 32 PDGCX models accurately reflects that of their prevalence in human GC samples, which is reported as 30~75% for ERBB1 positivity [50, 51], 15~22% for ERBB2 positivity [37, 50, 51], 60~70% for ERBB3 high expression [51, 52], 39~47% for PTEN loss [53, 54], 4–5% for FGFR2 amplification [8, 9, 37, 55], 20~70% for MET high expression [37, 56–59] and 0~10% for MET amplification [37, 56, 58–60]. This evidence concerns the gene ERBB2 and gastric cancer.